-
10:54:19 PM

GILD Stock News

09/19/23 8:30 AM
Nasdaq : GILD
covid-19
CHMP Adopts Positive Opinion to Extend the Use of Veklury® (Remdesivir) to Treat COVID-19 in People With Hepatic Impairment
Gilead Sciences, Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency granted a positive opinion for the use of Veklury ® to treat people with COVID-19 with mild to severe hepatic impairment. The European Commission will review the CHMP recommendation and, if adopted, Veklury will become the first and...
RHEA-AI
neutral
09/18/23 4:00 AM
Nasdaq : GILD
Kite’s Car T-cell Therapy Yescarta® Demonstrates High Response Rate and Durable Remission in ALYCANTE Study as Initial Treatment for Transplant Ineligible Patients With Relapsed/Refractory Large B-cell Lymphoma
Kite, a Gilead Company, today announced results from the Phase 2 ALYCANTE study, led and sponsored by the French collaborative group LYSA/LYSARC, for use of its chimeric antigen receptor T-cell therapy Yescarta ® in patients with relapsed/refractory large B-cell lymphoma after one prior line of therapy who were deemed ineligible for high-dose...
RHEA-AI
negative
09/10/23 3:01 AM
Nasdaq : GILD
clinical trial
Gilead’s Phase 2 EVOKE-02 Study of Trodelvy® (sacituzumab govitecan-hziy) in Combination With KEYTRUDA® (pembrolizumab) Demonstrates Promising Clinical Activity in First-Line Metastatic Non-Small Cell Lung Cancer
Gilead Sciences, Inc. today announced promising early data from the global, open-label, Phase 2 EVOKE-02 study evaluating Trodelvy ® in combination with Merck’ s anti-PD-1 therapy KEYTRUDA ® with or without platinum agents in patients with previously untreated advanced or metastatic non-small cell lung cancer without actionable genomic alterations.
RHEA-AI
negative
08/24/23 8:30 AM
Nasdaq : GILD
fda approvalcovid-19
FDA Approves Veklury® (Remdesivir) to Treat COVID-19 in People With Mild to Severe Hepatic Impairment With no Dose Adjustment
Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration approved a supplemental new drug application for the use of Veklury ® with no dose adjustments to treat COVID-19 in people with mild, moderate and severe hepatic impairment. This approval further supports the safety profile of Veklury as the first and only approved antiviral...
RHEA-AI
neutral